<?xml version="1.0" encoding="iso-8859-1"?>
<frameset>
<predicate lemma="decrease">
<roleset id="decrease.01" name="make smaller
" wordnet="2">
<roles>
  <role n="0" descr="agent
"/>
  <role n="1" descr="thing decrease
"/>
  <role n="2" descr="location
"/>
</roles>
<example src="MEDLINE" no="1">
<text>
Treatment with melatonin decreased lipid peroxide synthesis, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.

</text>
       <arg n="0">Treatment with melatonin
</arg>
       <arg n="1">lipid peroxide synthesis 
</arg>
       <arg n="2">-
</arg>
<fdg>
1	Treatment	treatment	subj:&gt;4	@SUBJ %NH N NOM SG
2	with	with	mod:&gt;1	@&lt;NOM %N&lt; PREP
3	melatonin	melatonin	pcomp:&gt;2	@&lt;P %NH N NOM SG
4	decreased	decrease	main:&gt;0	@+FMAINV %VA V PAST
5	lipid	lipid	attr:&gt;6	@A&gt; %&gt;N N NOM SG
6	peroxide	peroxide	attr:&gt;7	@A&gt; %&gt;N N NOM SG
7	synthesis	synthesis	obj:&gt;4	@OBJ %NH N NOM SG
8	,	,
9	and	and	cc:&gt;4	@CC %CC CC
10	permitted	permit	cc:&gt;4	@+FMAINV %VA V PAST
11	a	a	det:&gt;12	@DN&gt; %&gt;N DET SG
12	recovery	recovery	obj:&gt;10	@OBJ %NH N NOM SG
13	of	of	mod:&gt;12	@&lt;NOM-OF %N&lt; PREP
14	both	both	det:&gt;16	@DN&gt; %&gt;N DET PL
15	reduced	reduced	attr:&gt;16	@A&gt; %&gt;N A ABS
16	glutathione	glutathione	pcomp:&gt;13	@&lt;P %NH N NOM SG
17	and	and	cc:&gt;16	@CC %CC CC
18	scavenger	scavenger	attr:&gt;19	@A&gt; %&gt;N N NOM SG
19	enzyme	enzyme	attr:&gt;20	@A&gt; %&gt;N N NOM SG
20	activity	activity	cc:&gt;16	@&lt;P %NH N NOM SG
21	.     .
</fdg>
</example>
<example src="MEDLINE" no="2">
<text>
It was found that NLF from smokers contained decreased levels of Clara cell secretory protein, and increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.

</text>
       <arg n="0">-
</arg>
       <arg n="1">levels of Clara cell secretory protein
</arg>
       <arg n="2">-
</arg>
<fdg>
1	It	it	subj:&gt;2	@SUBJ %NH PRON NOM SG3
2	was	be	v-ch:&gt;3	@+FAUXV %AUX V PAST
3	found	find		@-FMAINV %VP EN
4	that	that		@CS %CS CS
5	NLF	nlf		@SUBJ %NH ABBR NOM SG	@OBJ %NH ABBR NOM SG	@PCOMPL-S %NH ABBR NOM SG	@PCOMPL-O %NH ABBR NOM SG	@&lt;NOM %N&lt; ABBR NOM SG
6	from	from		@&lt;NOM %N&lt; PREP
7	smokers	smoker	pcomp:&gt;6	@&lt;P %NH N NOM PL
8	contained	contain	mod:&gt;7	@-FMAINV %VP EN
9	decreased	decrease		@+FMAINV %VA V PAST
10	levels	level	obj:&gt;9	@OBJ %NH N NOM PL
11	of	of	mod:&gt;10	@&lt;NOM-OF %N&lt; PREP
12	Clara	clara	attr:&gt;13	@A&gt; %&gt;N N NOM SG
13	cell	cell	pcomp:&gt;11	@&lt;P %NH N NOM SG
14	secretory	secretory	attr:&gt;15	@A&gt; %&gt;N A ABS
15	protein	protein		@SUBJ %NH N NOM SG
16	,	,
17	and	and	cc:&gt;9	@CC %CC CC
18	increased	increase	cc:&gt;9	@+FMAINV %VA V PAST
19	proportions	proportion	obj:&gt;18	@OBJ %NH N NOM PL
20	of	of	mod:&gt;19	@&lt;NOM-OF %N&lt; PREP
21	a	a	det:&gt;23	@DN&gt; %&gt;N DET SG
22	truncated	truncated	attr:&gt;23	@A&gt; %&gt;N A ABS
23	variant	variant	pcomp:&gt;20	@&lt;P %NH N NOM SG
24	of	of	mod:&gt;23	@&lt;NOM-OF %N&lt; PREP
25	lipocortin-1	lipocortin-1	cc:&gt;27	@QN&gt; %&gt;N &lt;?&gt; NUM CARD
26	,	,
27	three	three	qn:&gt;29	@QN&gt; %&gt;N NUM CARD
28	acidic	acidic	attr:&gt;29	@A&gt; %&gt;N A ABS
29	forms	form	pcomp:&gt;24	@&lt;P %NH N NOM PL
30	of	of	mod:&gt;29	@&lt;NOM-OF %N&lt; PREP
31	alpha	alpha	pcomp:&gt;30	@&lt;P %NH N NOM SG
32	(	(
33	1	1	main:&gt;32	@NH %NH NUM CARD
34	)	)
35	-	-
36	antitrypsin	antitrypsin		@&lt;P %NH &lt;?&gt; A ABS
37	,	,
38	and	and	cc:&gt;36	@CC %CC CC
39	one	one	cc:&gt;36	@&lt;P %NH NUM CARD	@&lt;P %NH PRON NOM SG
40	phosphorylated	phosphorylate		@+FMAINV %VA V PAST
41	form	form	obj:&gt;40	@OBJ %NH N NOM SG
42	of	of	mod:&gt;41	@&lt;NOM-OF %N&lt; PREP
43	cystatin	cystatin	attr:&gt;44	@A&gt; %&gt;N &lt;?&gt; N NOM SG
44	S.	s.	attr:&gt;45	@A&gt; %&gt;N N NOM SG
45	Syntrophin	syntrophin		@SUBJ %NH &lt;?&gt; N NOM SG	@A&gt; %&gt;N &lt;?&gt; N NOM SG	@&lt;P %NH &lt;?&gt; N NOM SG
46	binds	bind		@SUBJ %NH N NOM PL	@&lt;P %NH N NOM PL	@+FMAINV %VA V PRES SG3
47	to	to		@&lt;NOM %N&lt; PREP	@ADVL %EH PREP
48	an	an	det:&gt;51	@DN&gt; %&gt;N DET SG
49	alternatively	alternatively	ad:&gt;50	@AD-A&gt; %E&gt; ADV
50	spliced	spliced	attr:&gt;51	@A&gt; %&gt;N A ABS
51	exon	exon	pcomp:&gt;47	@&lt;P %NH N NOM SG
52	of	of	mod:&gt;51	@&lt;NOM-OF %N&lt; PREP
53	dystrophin	dystrophin	pcomp:&gt;52	@&lt;P %NH N NOM SG
54	.     .
</fdg>
</example>
<example src="EMBO" no="1">
<text>
MEF2-binding sites have been reported in several cardiac promoters and their mutation was shown to decrease promoter activity in cardiomyocytes.

</text>
       <arg n="0">their mutation
</arg>
       <arg n="1">promoter activity
</arg>
       <arg n="2">[in] cardiomyocytes
</arg>
<fdg>
1	MEF2-binding	mef2-binding	attr:&gt;2	@A&gt; %&gt;N &lt;?&gt; A ABS
2	sites	site	subj:&gt;3	@SUBJ %NH N NOM PL
3	have	have	v-ch:&gt;4	@+FAUXV %AUX V PRES
4	been	be	v-ch:&gt;5	@-FAUXV %AUX EN
5	reported	report	main:&gt;0	@-FMAINV %VP EN
6	in	in	loc:&gt;5	@ADVL %EH PREP
7	several	several	det:&gt;9	@DN&gt; %&gt;N DET PL
8	cardiac	cardiac	attr:&gt;9	@A&gt; %&gt;N A ABS
9	promoters	promoter	pcomp:&gt;6	@&lt;P %NH N NOM PL
10	and	and	cc:&gt;5	@CC %CC CC
11	their	they	attr:&gt;12	@A&gt; %&gt;N PRON PERS GEN PL3
12	mutation	mutation	subj:&gt;13	@SUBJ %NH N NOM SG
13	was	be	v-ch:&gt;14	@+FAUXV %AUX V PAST
14	shown	show	cc:&gt;5	@-FMAINV %VP EN
15	to	to	pm:&gt;16	@INFMARK&gt; %AUX INFMARK&gt;
16	decrease	decrease	cnt:&gt;14	@-FMAINV %VA V INF
17	promoter	promoter	attr:&gt;18	@A&gt; %&gt;N N NOM SG
18	activity	activity	obj:&gt;16	@OBJ %NH N NOM SG
19	in	in	loc:&gt;16	@ADVL %EH PREP
&lt;NAME_cl="cell_type"&gt;
20	cardiomyocytes	cardiomyocyt*	pcomp:&gt;19	@&lt;P %NH &lt;?&gt; N NOM
21	.     .
</fdg>
</example>
<example src="EMBO" no="2">
<text>
If this distance of 30 amino acids is not maintained, as in human AspRS chimera#1, or in yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), the binding to tRNA is strongly affected and the protection is decreased, or even abolished in the case of human AspRS chimera#1 (Table).

</text>
       <arg n="0">-
</arg>
       <arg n="1">the protection
</arg>
       <arg n="2">-
</arg>
<fdg>
1	If	if	pm:&gt;10	@CS %CS CS
2	this	this	det:&gt;3	@DN&gt; %&gt;N DET DEM SG
3	distance	distance	subj:&gt;8	@SUBJ %NH N NOM SG
4	of	of	mod:&gt;3	@&lt;NOM-OF %N&lt; PREP
5	30	30	qn:&gt;7	@QN&gt; %&gt;N NUM CARD
6	amino	amino	attr:&gt;7	@A&gt; %&gt;N N NOM SG
7	acids	acid	pcomp:&gt;4	@&lt;P %NH N NOM PL
8	is	be	v-ch:&gt;10	@+FAUXV %AUX V PRES SG3
9	not	not	neg:&gt;8	@ADVL %EH NEG-PART
10	maintained	maintain		@-FMAINV %VP EN
11	,	,
12	as in	as in	ha:&gt;10	@ADVL %EH PREP
&lt;NAME_cl="protein"&gt;
13	human	human	attr:&gt;14	@A&gt; %&gt;N A ABS
14	AspRS	asprs	attr:&gt;15	@A&gt; %&gt;N N NOM SG
15	chimera	chimera		@SUBJ %NH N NOM SG	@A&gt; %&gt;N N NOM SG
16	#1	#1		@SUBJ %NH NUM CARD	@PCOMPL-S %NH NUM CARD	@PCOMPL-O %NH NUM CARD	@APP %NH NUM CARD	@&lt;P %NH NUM CARD	@&lt;NOM %N&lt; NUM CARD	@ADVL %EH NUM CARD
17	,	,
18	or	or		@CC %CC CC
19	in	in	cla:&gt;40	@ADVL %EH PREP
&lt;NAME_cl="protein"&gt;
20	yeast	yeast	attr:&gt;21	@A&gt; %&gt;N N NOM SG
21	LysRS	lysrs	attr:&gt;22	@A&gt; %&gt;N N NOM SG
22	chimera	chimera	pcomp:&gt;19	@&lt;P %NH N NOM SG
23	#1	#1	mod:&gt;22	@&lt;NOM %N&lt; NUM CARD
24	and	and		@CC %CC CC
&lt;NAME_cl="protein"&gt;
25	yeast	yeast	attr:&gt;26	@A&gt; %&gt;N N NOM SG
26	AsnRS	asnrs	attr:&gt;27	@A&gt; %&gt;N N NOM SG
27	chimera	chimera		@SUBJ %NH N NOM SG	@OBJ %NH N NOM SG	@PCOMPL-S %NH N NOM SG	@APP %NH N NOM SG	@A&gt; %&gt;N N NOM SG	@&lt;P %NH N NOM SG
28	#2	#2		@SUBJ %NH NUM CARD	@OBJ %NH NUM CARD	@PCOMPL-S %NH NUM CARD	@PCOMPL-O %NH NUM CARD	@APP %NH NUM CARD	@&lt;P %NH NUM CARD	@A&gt; %&gt;N NUM CARD	@&lt;NOM %N&lt; NUM CARD	@ADVL %EH NUM CARD
29	(	(
30	Figure	figure	attr:&gt;31	@A&gt; %&gt;N N NOM SG
31	5B	5b		@NH %NH NUM CARD	@APP %NH NUM CARD	@&lt;P %NH NUM CARD	@A&gt; %&gt;N NUM CARD
32	)	)
33	,	,
34	the	the	det:&gt;35	@DN&gt; %&gt;N DET
35	binding	binding	subj:&gt;38	@SUBJ %NH N NOM SG
36	to	to	mod:&gt;35	@&lt;NOM %N&lt; PREP
&lt;NAME_cl="RNA"&gt;
37	tRNA	trna	pcomp:&gt;36	@&lt;P %NH ABBR NOM SG
38	is	be	v-ch:&gt;40	@+FAUXV %AUX V PRES SG3
39	strongly	strongly	meta:&gt;40	@ADVL %EH ADV
40	affected	affect		@-FMAINV %VP EN
41	and	and	cc:&gt;40	@CC %CC CC
42	the	the	det:&gt;43	@DN&gt; %&gt;N DET
43	protection	protection	subj:&gt;44	@SUBJ %NH N NOM SG
44	is	be	v-ch:&gt;45	@+FAUXV %AUX V PRES SG3
45	decreased	decrease	cc:&gt;40	@-FMAINV %VP EN
46	,	,
47	or	or	cc:&gt;45	@CC %CC CC
48	even	even	meta:&gt;49	@ADVL %EH ADV
49	abolished	abolish	cc:&gt;45	@-FMAINV %VP EN
50	in	in	ha:&gt;49	@ADVL %EH PREP
51	the	the	det:&gt;52	@DN&gt; %&gt;N DET
52	case	case	pcomp:&gt;50	@&lt;P %NH N NOM SG
53	of	of	mod:&gt;52	@&lt;NOM-OF %N&lt; PREP
&lt;NAME_cl="protein"&gt;
54	human	human	attr:&gt;55	@A&gt; %&gt;N A ABS
55	AspRS	asprs	attr:&gt;56	@A&gt; %&gt;N N NOM SG
56	chimera	chimera		@SUBJ %NH N NOM SG	@APP %NH N NOM SG	@A&gt; %&gt;N N NOM SG	@&lt;P %NH N NOM SG
57	#1	#1		@SUBJ %NH NUM CARD	@PCOMPL-O %NH NUM CARD	@APP %NH NUM CARD	@&lt;P %NH NUM CARD	@A&gt; %&gt;N NUM CARD	@&lt;NOM %N&lt; NUM CARD	@ADVL %EH NUM CARD
58	(	(
59	Table	table		@NH %NH N NOM SG
60	)	)
61	.     .
</fdg>
</example>
<example src="EMBO" no="3">
<text>
In contrast, only low levels of the truncated RAP1 peptides were detected (consistent with lower expression levels and decreased methionine content), and neither RAP2 nor RAP3 was co-immunoprecipitated in the RAP1 mutants.

</text>
       <arg n="0">-
</arg>
       <arg n="1">methionine content
</arg>
       <arg n="2">-
</arg>
<fdg>
1	In	in	cla:&gt;13	@ADVL %EH PREP
2	contrast	contrast	pcomp:&gt;1	@&lt;P %NH N NOM SG
3	,	,
4	only	only	meta:&gt;6	@ADVL %EH ADV
5	low	low	attr:&gt;6	@A&gt; %&gt;N A ABS
6	levels	level	subj:&gt;12	@SUBJ %NH N NOM PL
7	of	of	mod:&gt;6	@&lt;NOM-OF %N&lt; PREP
8	the	the	det:&gt;11	@DN&gt; %&gt;N DET
&lt;NAME_cl="protein"&gt;
9	truncated	truncated	attr:&gt;10	@A&gt; %&gt;N A ABS
10	RAP1	rap1	attr:&gt;11	@A&gt; %&gt;N N NOM SG
11	peptides	peptide	pcomp:&gt;7	@&lt;P %NH N NOM PL
12	were	be	v-ch:&gt;13	@+FAUXV %AUX V PAST PL
13	detected	detect	main:&gt;0	@-FMAINV %VP EN
14	(	(
15	consistent	consistent		@SUBJ %NH A ABS	@OBJ %NH A ABS	@&lt;NOM %N&lt; A ABS	@NH %NH A ABS
16	with	with	mod:&gt;15	@&lt;NOM %N&lt; PREP
17	lower	low	attr:&gt;18	@A&gt; %&gt;N A CMP
18	expression	expression	attr:&gt;19	@A&gt; %&gt;N N NOM SG
19	levels	level	pcomp:&gt;16	@&lt;P %NH N NOM PL
20	and	and		@CC %CC CC
21	decreased	decrease		@+FMAINV %VA V PAST
&lt;NAME_cl="protein"&gt;
22	methionine	methionine	attr:&gt;23	@A&gt; %&gt;N N NOM SG
23	content	content	obj:&gt;21	@OBJ %NH N NOM SG
24	)	)
25	,	,
26	and	and		@CC %CC CC
27	neither	neither	ad:&gt;28	@AD-A&gt; %E&gt; ADV
&lt;NAME_cl="protein"&gt;
28	RAP2	rap2		@SUBJ %NH N NOM SG	@OBJ %NH N NOM SG	@APP %NH N NOM SG	@&lt;P %NH N NOM SG
29	nor	nor		@CC %CC CC
&lt;NAME_cl="protein"&gt;
30	RAP3	rap3		@SUBJ %NH N NOM SG	@OBJ %NH N NOM SG	@APP %NH N NOM SG	@&lt;P %NH N NOM SG
31	was	be		@+FMAINV %VA V PAST
32	co-immunoprecipitated	co-immunoprecipitated	comp:&gt;31	@PCOMPL-S %NH &lt;?&gt; A ABS
33	in	in	loc:&gt;31	@&lt;NOM %N&lt; PREP	@ADVL %EH PREP
34	the	the	det:&gt;36	@DN&gt; %&gt;N DET
&lt;NAME_cl="protein"&gt;
35	RAP1	rap1	attr:&gt;36	@A&gt; %&gt;N N NOM SG
36	mutants	mutant	pcomp:&gt;33	@&lt;P %NH N NOM PL
37	.     .
</fdg>
</example>
<example src="PNAS" no="1">
<text>
In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, the RELN mRNA content was significantly decreased (4050%; see Table 2).

</text>
       <arg n="0">the RELN mRNA content 
</arg>
       <arg n="1">-
</arg>
       <arg n="2">-
</arg>
<fdg>
1	In	in	cla:&gt;21	@ADVL %EH PREP
2	brain	brain	attr:&gt;3	@A&gt; %&gt;N N NOM SG
3	areas	area	pcomp:&gt;1	@&lt;P %NH N NOM PL
4	of	of	mod:&gt;3	@&lt;NOM-OF %N&lt; PREP
5	schizophrenia	schizophrenia	attr:&gt;6	@A&gt; %&gt;N N NOM SG
6	patients	patient	pcomp:&gt;4	@&lt;P %NH N NOM PL
7	homologous	homologous	mod:&gt;6	@&lt;NOM %N&lt; A ABS
8	to	to		@&lt;NOM %N&lt; PREP	@ADVL %EH PREP
9	those	that	pcomp:&gt;8	@&lt;P %NH PRON DEM PL
10	of	of	mod:&gt;9	@&lt;NOM-OF %N&lt; PREP
11	the	the	det:&gt;13	@DN&gt; %&gt;N DET
12	nonpsychiatric	nonpsychiatric	attr:&gt;13	@A&gt; %&gt;N A ABS
13	subjects	subject	pcomp:&gt;10	@&lt;P %NH N NOM PL
14	,	,
15	the	the	det:&gt;18	@DN&gt; %&gt;N DET
16	RELN	reln	attr:&gt;17	@A&gt; %&gt;N N NOM SG
17	mRNA	mrna	attr:&gt;18	@A&gt; %&gt;N ABBR NOM SG
18	content	content	subj:&gt;19	@SUBJ %NH N NOM SG
19	was	be	v-ch:&gt;21	@+FAUXV %AUX V PAST
20	significantly	significantly	meta:&gt;21	@ADVL %EH ADV
21	decreased	decrease	main:&gt;0	@-FMAINV %VP EN
22	(	(
23	40 - 	40 - 	qn:&gt;24	@QN&gt; %&gt;N NUM CARD
24	50%	50%	qua:&gt;21	@ADVL %EH NUM CARD
25	;	;
26	see	see	cc:&gt;0	@+FMAINV %VA V IMP
27	Table	table	obj:&gt;26	@OBJ %NH N NOM SG
28	2	2	qua:&gt;26	@ADVL %EH NUM CARD
29	)	)
30	.     .
</fdg>
</example>
</roleset>

<roleset id="decrease.02" name="" wordnet="1">
<roles>
  <role n="1" descr="theme
"/>
  <role n="2" descr="amount decreased 			
"/>
  <role n="3" descr="location
"/>
</roles>
<example src="MEDLINE" no="1">
<text>
Concomitantly, the levels of acetylcholine were found to decrease by 37.8% in the lead-treated animals as compared to the controls.

</text>
       <arg n="1">the levels of acetylcholine
</arg>
       <arg n="2">[by] 37.8%
</arg>
       <arg n="3">the lead-treated animals
</arg>
<fdg>
1	Concomitantly	concomitantly		@ADVL %EH ADV
2	,	,
3	the	the	det:&gt;4	@DN&gt; %&gt;N DET
4	levels	level	subj:&gt;7	@SUBJ %NH N NOM PL

5	of	of	mod:&gt;4	@&lt;NOM-OF %N&lt; PREP
6	acetylcholine	acetylcholine	pcomp:&gt;5	@&lt;P %NH N NOM SG
7	were	be	v-ch:&gt;8	@+FAUXV %AUX V PAST PL
8	found	find	main:&gt;0	@-FMAINV %VP EN
9	to	to	pm:&gt;10	@INFMARK&gt; %AUX INFMARK&gt;
10	decrease	decrease	cnt:&gt;8	@-FMAINV %VA V INF
11	by	by	ha:&gt;10	@ADVL %EH PREP
12	37.8%	37.8%	pcomp:&gt;11	@&lt;P %NH NUM CARD
13	in	in	mod:&gt;12	@&lt;NOM %N&lt; PREP
14	the	the	det:&gt;16	@DN&gt; %&gt;N DET
15	lead-treated	lead-treated	attr:&gt;16	@A&gt; %&gt;N A ABS
16	animals	animal	pcomp:&gt;13	@&lt;P %NH N NOM PL
17	as	as	pm:&gt;18	@CS %CS CS
18	compared	compare	man:&gt;10	@-FMAINV %VP EN
19	to	to	ha:&gt;18	@ADVL %EH PREP
20	the	the	det:&gt;21	@DN&gt; %&gt;N DET
21	controls	control	pcomp:&gt;19	@&lt;P %NH N NOM PL
22	.     .
</fdg>
</example>
<example src="MEDLINE" no="2">
<text>
In contrast, GP only decreased by 12.4% +/-3.9% (1.97 +/-0.13 to 1.73 +/-0.13 mg/kg/min; not significant [NS]) in those who had little to no increase in plasma citrulline concentration.

</text>
       <arg n="1">GP
</arg>
       <arg n="2">[by] 12.4% +/- 3.9% 
</arg>
       <arg n="3">in those who had little to no increase in plasma citrulline concentration
</arg>
       <arg n="M-ADV">only
</arg>
<fdg>
1	In	in	cla:&gt;6	@ADVL %EH PREP
2	contrast	contrast	pcomp:&gt;1	@&lt;P %NH N NOM SG
3	,	,
4	GP	gp	subj:&gt;6	@SUBJ %NH ABBR NOM SG
5	only	only	meta:&gt;6	@ADVL %EH ADV
6	decreased	decrease	main:&gt;0	@+FMAINV %VA V PAST
7	by	by	ha:&gt;6	@ADVL %EH PREP
8	12.4%	12.4%	pcomp:&gt;7	@&lt;P %NH NUM CARD
9	+	+		@CC %CC CC
10	/	/	
11	-	-
12	&lt;s&gt;	&lt;s&gt;
1	3.9%	3.9%		@NH %NH NUM CARD	@ADVL %EH NUM CARD
2	(	(
3	1.97	1.97	main:&gt;2	@APP %NH NUM CARD
4	+	+		@CC %CC CC
5	/	/	
6	-	-
7	0.13	0.13		@&lt;P %NH NUM CARD
8	to	to	mod:&gt;7	@ADVL %EH PREP
9	1.73	1.73	pcomp:&gt;8	@&lt;P %NH NUM CARD
10	+	+	cc:&gt;9	@CC %CC CC
11	/	/	
12	-	-
13	0.13	0.13		@QN&gt; %&gt;N NUM CARD
14	mg/kg/min	mg/kg/min	cc:&gt;9	@&lt;P %NH &lt;?&gt; N NOM SG
15	;	;
16	not	not		@ADVL %EH NEG-PART
17	significant	significant		@A&gt; %&gt;N A ABS	@&lt;NOM %N&lt; A ABS	@NH %NH A ABS
18	[	[
19	NS	ns		@NH %NH ABBR NOM SG
20	])	])
21	in	in		@ADVL %EH PREP
22	those	that	pcomp:&gt;21	@&lt;P %NH PRON DEM PL
23	who	who	subj:&gt;24	@SUBJ %NH &lt;Rel&gt; PRON WH NOM
24	had	have	mod:&gt;22	@+FMAINV %VA V PAST
25	little	little	obj:&gt;24	@OBJ %NH PRON ABS SG
26	to	to	goa:&gt;24	@ADVL %EH PREP
27	no	no	det:&gt;28	@DN&gt; %&gt;N DET
28	increase	increase	pcomp:&gt;26	@&lt;P %NH N NOM SG
29	in	in	mod:&gt;28	@&lt;NOM %N&lt; PREP
30	plasma	plasma	attr:&gt;31	@A&gt; %&gt;N N NOM SG
31	citrulline	citrulline	attr:&gt;32	@A&gt; %&gt;N &lt;?&gt; N NOM SG
32	concentration	concentration	pcomp:&gt;29	@&lt;P %NH N NOM SG
33	.     .
</fdg>
</example>
<example src="PNAS" no="1">
<text>
Furthermore, the CD3? expression decreased by mixing normal T cells with TBM-M?s in a cell-number-dependent manner (Fig.2B).

</text>
       <arg n="1">the CD3? expression 
</arg>
       <arg n="2">-
</arg>
       <arg n="3">-
</arg>
<fdg>
1	Furthermore	furthermore		@ADVL %EH ADV
2	,	,
3	the	the	det:&gt;4	@DN&gt; %&gt;N DET
4	CD3	cd3		@NH %NH N NOM SG
5	?	?
6	&lt;s&gt;	&lt;s&gt;
7	expression	expression	main:&gt;0	@NH %NH N NOM SG
8	decreased	decrease	mod:&gt;1	@-FMAINV %VP EN
9	by	by	man:&gt;2	@ADVL %EH PREP
10	mixing	mix	pcomp:&gt;3	@&lt;P-FMAINV %VA ING
11	normal	normal	attr:&gt;6	@A&gt; %&gt;N A ABS
12	T	t	attr:&gt;7	@A&gt; %&gt;N ABBR NOM SG
13	cells	cell	obj:&gt;4	@OBJ %NH N NOM PL
14	with	with	phr:&gt;4	@ADVL %EH PREP
15	TBM-M	tbm-m	pcomp:&gt;8	@&lt;P %NH N NOM SG
16	?	?
17	&lt;s&gt;	&lt;s&gt;
18	s	s		@NH %NH ABBR NOM SG	@&lt;NOM %N&lt; ABBR NOM SG
19	in	in		@&lt;NOM %N&lt; PREP	@ADVL %EH PREP
20	a	a	det:&gt;5	@DN&gt; %&gt;N DET SG
21	cell-number-dependent	cell-number-dependent	attr:&gt;5	@A&gt; %&gt;N &lt;?&gt; A ABS
22	manner	manner	pcomp:&gt;2	@&lt;P %NH N NOM SG
23	(	(
24	Fig.	fig.	mod:&gt;6	@APP %NH ABBR NOM SG
25	2B	2b	mod:&gt;7	@&lt;NOM %N&lt; NUM CARD
26	)	)
27	.     .
</fdg>
</example>
</roleset>

</predicate>
</frameset>
